Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether it is possible to augment the response of
patients with HBeAg-positive chronic hepatitis B to entecavir by using a temporary
peginterferon alpha-2a add-on strategy